MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Health Canada has approved the use of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in selecting patients for PSMA¹-targeted radionuclide therapy.

The label expansion means that Illuccix is now approved in Canada to select patients with progressive metastatic castration-resistant prostate cancer (mCRPC) for treatment with the only approved PSMA-targeted radionuclide therapy (lutetium (¹⁷⁷Lu) vipivotide tetraxetan, or Pluvicto®²). To qualify for PSMA-targeted therapy, patients must be imaged with an approved gallium-based PSMA-PET³ agent⁴, such as Illuccix.